ABSTRACT
Objective To assess the efficacy of policies designed to reduce the risk of international travelers importing SARS-CoV-2 into a country.
Method We developed a simulation model and compared mandatory quarantine, testing, and combined quarantine and testing. We assessed the sensitivity of policy effectiveness to the timing of testing, compliance with quarantine and isolation, and other factors.
Results In the base scenario, a 2-day quarantine reduced more risk than testing alone. The effectiveness of a 5-day quarantine requirement with perfect compliance was similar to a 14-day quarantine with moderate compliance. Testing 72h before arrival reduced less than 10% of in-country transmission risk across all scenarios. The addition of testing to quarantine added value for shorter quarantine lengths, when testing compliance was enforced, and when testing was performed near the end of quarantine.
Conclusions Quarantine is more effective at preventing SARS-CoV-2 transmission from arriving travelers than testing alone, but testing combined with quarantine can add value if longer quarantine requirements are infeasible. Enforcing compliance with quarantine and isolation is critical. Requiring a negative test up to 72h before arrival may have limited effectiveness.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding specific to this publication was received. WAR was supported by a Stanford Interdisciplinary Graduate Fellowship; DLB was supported by a Canada Research Chair in Health Informatics and Data Science.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This analysis was based on public data and was exempt from institutional ethics review.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data and materials have been uploaded to a public repository.
